Viking Therapeutics

Yahoo Finance • 19 hours ago

Down 44%, Should You Buy the Dip on Viking Therapeutics?

Key Points Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase 3 trials, and data so far a... Full story

Yahoo Finance • 2 days ago

4 Healthcare Stocks to Buy Now

Key Points Two gene-editing companies are advancing therapies, with one generating commercial sales and both approaching major regulatory milestones. An AI drug discovery company is approaching multiple trial readouts in late 2025 that co... Full story

Yahoo Finance • 5 days ago

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero

Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t... Full story

Yahoo Finance • 6 days ago

Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory

We came across a bullish thesis on Collegium Pharmaceutical, Inc. on The Catholic Capitalist’s Substack by Logan Shearer. In this article, we will summarize the bulls’ thesis on COLL. Collegium Pharmaceutical, Inc.'s share was trading at $... Full story

Yahoo Finance • 8 days ago

Noteworthy Monday Option Activity: AAOI, VKTX, ADBE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Applied Optoelectronics Inc (Symbol: AAOI), where a total volume of 39,702 contracts has been traded thus far today, a co... Full story

Yahoo Finance • 14 days ago

BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best strong buy stocks to invest in according to Wall Street. On September 22, BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a $12... Full story

Yahoo Finance • 14 days ago

Why This Beaten-Down GLP-1 Stock Could Be a Steal

Key Points Viking Therapeutics' shares plunged after mixed phase 2 results for a GLP-1 candidate. However, the data wasn't nearly as bad as the market's reaction suggested. Viking could soar on future progress with this and other candidat... Full story

Yahoo Finance • 22 days ago

Analysts Forecast 11% Upside For The Holdings of IWS

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 28 days ago

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory

We came across a bullish thesis on Viking Therapeutics, Inc. on Value investing subreddit by Remarkable-Ad5326. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was trading at $25.27 as of Sep... Full story

Yahoo Finance • last month

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • last month

Jim Cramer Recommends Eli Lilly Over Viking Therapeutics

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer shared insights on. When a caller asked about the company during the lightning round, Cramer commented: “No, no, no. We have Eli Lilly. Why do we have to settle? Let’... Full story

Yahoo Finance • 2 months ago

Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)

Key Points According to recent filings, the Duquesne Family Office initiated a position in Viking Therapeutics. Viking is a clinical-stage biotech with several obesity-care candidates in its pipeline. The obesity-care market is largely do... Full story

Yahoo Finance • 2 months ago

Eli Lilly's 'Surprising Development' In Obesity Just Slammed Viking, Novo Stocks

Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful Phase 3 study. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump

Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful Phase 3 study. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: Novo Nordisk, Medtronic, Novavax in focus

Wall Street jumped sharply on Friday, with the Dow hitting a fresh all-time high as investors welcomed Federal Reserve Chair Jerome Powell’s remarks at Jackson Hole. The S&P 500 Health Care Index Sector (NYSEARCA:XLV [https://seekingalpha... Full story

Yahoo Finance • 2 months ago

Investing.com’s stocks of the week

Investing.com -- It was shaping up to be a negative week until Federal Reserve Chair Jerome Powell’s speech during the central bank’s annual gathering in Jackson Hole, Wyoming. Nevertheless, there were still some big moves in both directi... Full story

Yahoo Finance • 2 months ago

Here's Why Viking Therapeutics Bounced Back Today

Key Points The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking may decide to take VK2735 (oral form) through phase 3, or a peer could step... Full story

Yahoo Finance • 2 months ago

Viking Therapeutics shorts gain $0.5B amid selloff: report

[Red arrow And dollar finance decline graph- Stock image] Baris-Ozer Investors betting against Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) netted a one-day paper profit of $521M as the shares of the San Diego,... Full story

Yahoo Finance • 2 months ago

Morgan Stanley reiterates Overweight rating on Viking Therapeutic stock

Investing.com - Morgan Stanley has reiterated an Overweight rating and $98.00 price target on Viking Therapeutic (NASDAQ:VKTX), currently trading at $24.64, following clinical trial results for its oral weight loss drug VK2735. According t... Full story

Yahoo Finance • 2 months ago

Viking Therapeutics stock rating reiterated as Buy by Jefferies

Investing.com - Jefferies has reiterated its Buy rating and $101.00 price target on Viking Therapeutics (NASDAQ:VKTX), maintaining its positive outlook on the $2.8 billion market cap biopharmaceutical company. According to InvestingPro dat... Full story